Brian O Mahony/X
May 10, 2025, 10:31
Brian O Mahony Raises Concerns Over Lack of Evidence in Moderate Hemophilia Treatment
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Hermans WFHCCS2025 Moderate haemophilia are the severe patients of today but there is limited evidence or few clinical trials showing benefit of treatment in moderate. Most evidence is in severe patients.”
Find More Posts on Hemostasis Today.
-
Oct 9, 2026, 12:48Santiago Cepeda Chafla: CereBleed Simplifies Brain Hemorrhage Assessment
-
Oct 9, 2026, 12:34Abdul Muqtadir Abbasi: Pancytopenia Is a Finding, Not a Diagnosis
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research